Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18477563
Matsushima-Nishiwaki R, et al. (2008) Phosphorylated heat shock protein 27 represses growth of hepatocellular carcinoma via inhibition of extracellular signal-regulated kinase. J Biol Chem 283, 18852-60 18477563
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S359-p - DUSP1 (human)
Modsite: SALSYLQsPITTsPS SwissProt Entrez-Gene
Orthologous residues
DUSP1 (human): S359‑p, DUSP1 (mouse): S359‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) augment treatment-induced increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) inhibit treatment-induced increase

S15-p - HSP27 (human)
Modsite: FsLLrGPsWDPFrDW SwissProt Entrez-Gene
Orthologous residues
HSP27 (human): S15‑p, HSP27 (mouse): S15‑p, HSP27 (rat): S15‑p, HSP27 (pig): S15‑p, HSP27 (hamster): S15‑p, HSP27 (chicken): S15‑p, HSP27 (dog): S15‑p, HSP27 (cow): S15‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  apoptosis, altered, cell growth, altered, transcription, altered
Comments:  Raf/MEK/ERK and p38/MKP-1 phosphorylation

S78-p - HSP27 (human)
Modsite: PAysRALsRQLssGV SwissProt Entrez-Gene
Orthologous residues
HSP27 (human): S78‑p, HSP27 (mouse): N82‑p, HSP27 (rat): N82‑p, HSP27 (pig): S80‑p, HSP27 (hamster): N86‑p, HSP27 (chicken): S77‑p, HSP27 (dog): S82‑p, HSP27 (cow): S74‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  apoptosis, altered, cell growth, altered, transcription, altered
Comments:  Raf/MEK/ERK and p38/MKP-1 phosphorylation

S82-p - HSP27 (human)
Modsite: RALsRQLssGVsEIr SwissProt Entrez-Gene
Orthologous residues
HSP27 (human): S82‑p, HSP27 (mouse): S86‑p, HSP27 (rat): S86‑p, HSP27 (pig): S84‑p, HSP27 (hamster): S90‑p, HSP27 (chicken): S80‑p, HSP27 (dog): S86‑p, HSP27 (cow): S78‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  apoptosis, altered, cell growth, altered, transcription, altered
Comments:  Raf/MEK/ERK and p38/MKP-1 phosphorylation

S218-p - MEK1 (human)
Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S218‑p, MEK1 iso2 (human): S192‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) inhibit treatment-induced increase

S222-p - MEK1 (human)
Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S222‑p, MEK1 iso2 (human): S196‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) inhibit treatment-induced increase

S222-p - MEK2 (human)
Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): S222‑p, MEK2 (mouse): S222‑p, MEK2 (rat): S222‑p, MEK2 (chicken): S220‑p, MEK2 (cow): S222‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) inhibit treatment-induced increase

S226-p - MEK2 (human)
Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): S226‑p, MEK2 (mouse): S226‑p, MEK2 (rat): S226‑p, MEK2 (chicken): S224‑p, MEK2 (cow): S226‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) inhibit treatment-induced increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) augment treatment-induced increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  liver cancer, hepatocellular carcinoma
Relevant cell lines - cell types - tissues:  Huh7 (hepatic), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
TNF HSP27 (human) augment treatment-induced increase